122 related articles for article (PubMed ID: 12729997)
21. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
[TBL] [Abstract][Full Text] [Related]
22. Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae.
Chan WC; Li RC; Ling JM; Cheng AF; Schentag JJ
J Antimicrob Chemother; 1999 Jan; 43(1):55-60. PubMed ID: 10381101
[TBL] [Abstract][Full Text] [Related]
23. Meropenem susceptibility of Neisseria meningitidis and Streptococcus pneumoniae from meningitis patients in The Netherlands.
van de Beek D; Hensen EF; Spanjaard L; de Gans J; Enting RH; Dankert J
J Antimicrob Chemother; 1997 Dec; 40(6):895-7. PubMed ID: 9462445
[TBL] [Abstract][Full Text] [Related]
24. Ertapenem: a new carbapenem.
Odenholt I
Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of ertapenem-EMB Agar with traditional methods for screening carbapenem-resistant Klebsiella pneumoniae from rectal swabs].
Perçin D; Colakoğlu S; Durmaz S; Ekincioğlu P
Mikrobiyol Bul; 2012 Oct; 46(4):546-52. PubMed ID: 23188568
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
Wexler HM; Engel AE; Glass D; Li C
Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
[TBL] [Abstract][Full Text] [Related]
27. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
Piddock LJ; Johnson MM; Webber MA
J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
[TBL] [Abstract][Full Text] [Related]
28. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
[TBL] [Abstract][Full Text] [Related]
30. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
[TBL] [Abstract][Full Text] [Related]
31. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
32. Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin.
Heer C; Stuertz K; Reinert RR; Mäder M; Nau R
Infection; 2000; 28(1):13-20. PubMed ID: 10697785
[TBL] [Abstract][Full Text] [Related]
33. Activity of meropenem and other antimicrobial agents against uncommon gram-negative organisms.
Clark RB; Joyce SE
J Antimicrob Chemother; 1993 Aug; 32(2):233-7. PubMed ID: 8226425
[TBL] [Abstract][Full Text] [Related]
34. Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.
Giacometti A; Siquini FM; Cirioni O; Petroni S; Scalise G
Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):315-8. PubMed ID: 8070438
[TBL] [Abstract][Full Text] [Related]
35. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
Powell M; Seetulsingh P; Williams JD
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
Sader HS; Jones RN
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
[TBL] [Abstract][Full Text] [Related]
38. Pneumococcal susceptibility to meropenem.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 1996 May; 37(5):1036-7. PubMed ID: 8737158
[No Abstract] [Full Text] [Related]
39. Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
Kim BN; Woo JH; Kim YS; Ryu J; Kim MN; Pai CH
Chemotherapy; 2000; 46(5):303-8. PubMed ID: 10965094
[TBL] [Abstract][Full Text] [Related]
40. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
